Analyst Insights: Insulet, Illumina, Jabil Circuit Feb. 13th

Insulet Corporation(NASDAQ:PODD): After Insulet reported weaker than expected Q4 results, Barrington reduced its FY12 estimates but the firm expects the company’s stock to outperform its group in 2012. The firm believes that the company’s risk will decline this year and it reiterates an Outperform rating.

Illumina Inc.(NASDAQ:ILMN): Leerink views today’s FY13 budget proposal of $30.7B for the National Institutes of Health as an incremental positive for life science companies exposed to U.S. government-backed research. The firm notes the FY13 proposed budget is equal to the FY12 budget. Leerink highlights Illumina (NASDAQ:ILMN), Affymetrix (NASDAQ:AFFX), Fluidigm (NASDAQ:FLDM), Life Technologies (NASDAQ:LIFE), Thermo Fisher (NYSE:TMO) and Bruker (NASDAQ:BRKR) as having 15% exposure or greater to U.S. government-backed research.

Jabil Circuit Inc.(NYSE:JBL): Argus increased its target on Jabil Circuit (NYSE:JBL) after the company’s CEO hinted that Apple (NASDAQ:AAPL) had become Jabil’s third 10%-plus customer.The firm expects Jabil’s revenue to grow fast than that of its peers, and it maintains a Buy rating on the shares.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at